Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Published:2019-04 Issue:4 Volume:30 Page:589-596
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Stein J.E.,Soni A.,Danilova L.,Cottrell T.R.,Gajewski T.F.,Hodi F.S.,Bhatia S.,Urba W.J.,Sharfman W.H.,Wind-Rotolo M.,Edwards R.,Lipson E.J.,Taube J.M.

Funder

Melanoma Research Alliance

JMT

Harry J. Lloyd Trust

Emerson Collective

Moving for Melanoma of Delaware

EJL

Barney Family Foundation

Laverna Hahn Charitable Trust

Roland Park Country School

Bristol-Myers Squibb

JES

Sidney Kimmel Cancer Center Core

National Cancer Institute

NIH

Bloomberg-Kimmel Institute for Cancer Immunotherapy

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/4/589/28564906/mdz019.pdf

Reference21 articles.

1. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC);Cottrell;Ann Oncol,2018

2. Neoadjuvant PD-1 blockade in resectable lung cancer;Forde;N Engl J Med,2018

3. Preliminary results from the international neoadjuvant melanoma consortium (INMC);Menzies;J Clin Oncol,2017

4. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma;Tetzlaff;Ann Oncol,2018

5. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint;Hellmann;Lancet Oncol,2014

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

2. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers;Journal of Clinical Oncology;2024-03-20

3. Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade;2024-01-04

4. Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma;2024

5. Association between pathologic response and survival after neoadjuvant therapy in lung cancer;Nature Medicine;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3